0
Sign In  | Subscribe
16 January 2001, Vol 134, No. 2>
Summaries for Patients | 16 January 2001

Ursodiol Is Associated with Fewer Precancerous Abnormalities of the Colon in Certain Patients with Ulcerative Colitis FREE

[+] Article and Author Information

The summary below is from the full report titled “Ursodiol Use Is Associated with Lower Prevalence of Colonic Neoplasia in Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis.” It is in the 16 January 2001 issue of Annals of Internal Medicine (volume 134, pages 89-95). The authors are BY Tung, MJ Emond, RC Haggitt, MP Bronner, MB Kimmey, KV Kowdley, and TA Brentnall.


Ann Intern Med. 2001;134(2):S69-. doi:10.7326/0003-4819-134-2-200101160-00003
Text Size: A A A

What is the problem and what is known about it so far?

Ulcerative colitis (UC) is a disease in which chronic inflammation of the colon leads to diarrhea, bleeding into the stool, abdominal pain, difficulties with nutrition, and an increased risk for colon cancer. Primary sclerosing cholangitis (PSC) is an inflammatory disease of the biliary tract, the system that brings bile from the liver to the gut. Approximately 2% to 4% of patients with UC also have PSC. Nearly half of patients with both UC and PSC will develop colon cancer or precancerous changes of the colon (dysplasia) within 25 years of diagnosis of UC. This risk for cancer is so high that some patients are willing to have their colons removed surgically as a preventive measure. Strategies to decrease the risk for colon cancer, other than removal of the colon, could benefit patients with both UC and PSC. Ursodiol is a drug that has been useful in treating liver abnormalities in patients with PSC. Ursodiol decreases the amount of bile acids that reach the colon; this is important because bile acids may play a role in the development of colon cancer.

Why did the researchers do this particular study?

To find out whether patients with UC and PSC who receive ursodiol are less likely to develop colon cancer or precancerous changes of the colon than those who do not.

Who was studied?

Fifty-nine patients with UC and PSC who received care in a teaching hospital.

How was the study done?

The researchers determined whether patients were taking ursodiol and collected information about their medical histories. All of the patients had a procedure that examined the inside of the colon (colonoscopy) every 1 to 3 years to look for cancer or precancerous changes.

What did the researchers find?

Patients who took ursodiol were less likely to develop colon cancer or precancerous changes than those who did not. This relationship remained even after accounting for the patients' age, duration of UC and PSC, severity of liver disease, and use of other medications.

What were the limitations of the study?

It is unclear whether similar results would occur in patients who have UC only. The decision to treat with ursodiol was made by patients' individual doctors rather than as part of a randomized study. Patients who received ursodiol may therefore have differed from those who did not in ways that the researchers could not account for.

What are the implications of the study?

Patients with UC and PSC who take ursodiol appear less likely to develop cancer or precancerous changes of the colon than those who do not take ursodiol. A randomized trial should be done to determine whether ursodiol is effective prevention for colon cancer in patients with UC.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general jounals
BMJ 2010;341:c5893-c1494.

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Want to Subscribe?

Learn more about subscription options

Register Now for a free account
Advertisement

Related Content

Customize your page view by dragging & repositioning the boxes below.

Journal Club
Topic Collections
PubMed Articles
Small duct autoimmune sclerosing cholangitis and Crohn colitis in a 10-year-old child. A case report and review of the literature.
Diagnostic pathology Issue date: 2012
Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: a meta-analysis.
Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology Issue date: 2012 Apr

Annals of Internal Medicine

Other Resources

Copyright © 2013 The American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Want to Subscribe?

Learn more about subscription options

Register Now for a free account
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)